3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Other
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Other neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Oxaliplatin
1413
Fluorouracil
1301
Capecitabine
1087
Gemcitabine
1045
Leucovorin
932
Irinotecan
818
Bevacizumab
804
Cisplatin
669
Radiotherapy
536
Cetuximab
470
pembrolizumab
428
Paclitaxel
390
Nivolumab
337
130-nm albumin-bound paclitaxel
325
Drug Therapy
314
Docetaxel
287
S 1 (combination)
274
Sorafenib
266
Folfox protocol
261
Albumin-Bound Paclitaxel
259
sintilimab
211
durvalumab
210
Surgical Procedures, Operative
204
tislelizumab
203
Radiosurgery
202
lenvatinib
201
apatinib
200
Carboplatin
187
Magnetic Resonance Spectroscopy
183
regorafenib
181
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
High-Intensity Focused Ultrasound Ablation
×
Gastrointestinal
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled